Trials / Sponsors / Beijing GoBroad Hospital
Beijing GoBroad Hospital
Academic / Other · 31 registered clinical trials — 31 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrin Advanced Neuroendocrine Carcinoma | Phase 2 | 2026-04-30 |
| Recruiting | Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension | Phase 1 / Phase 2 | 2026-03-18 |
| Recruiting | Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 | 2026-03-15 |
| Recruiting | Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-s Gastrointestinal Cancer | Phase 1 | 2026-02-01 |
| Recruiting | TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors Solid Cancer, GPC3 Positive Hepatocellular Carcinoma | EARLY_Phase 1 | 2025-12-18 |
| Recruiting | To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esoph Gastroesophageal Junction Adenocarcinoma | — | 2025-10-22 |
| Recruiting | A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases Systemic Sclerosis (SSc), Primary Sjogren's Syndrome | Phase 1 | 2025-10-01 |
| Not Yet Recruiting | Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients B Cell Lymphoma | — | 2025-09-20 |
| Recruiting | Exploratory Clinical Study on the Safety of STR-P004 Autoimmune Diseases | N/A | 2025-09-16 |
| Recruiting | Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory | EARLY_Phase 1 | 2025-08-05 |
| Recruiting | A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Re T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2025-07-09 |
| Not Yet Recruiting | A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma Neuroendocrine Carcinomas (NEC) | Phase 4 | 2025-06-20 |
| Recruiting | A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc) | Phase 1 | 2025-06-01 |
| Recruiting | CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL) | Phase 1 / Phase 2 | 2025-06-01 |
| Recruiting | Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 | 2025-05-25 |
| Recruiting | Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 | 2025-05-25 |
| Not Yet Recruiting | A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer Advanced Extrapulmonary Neuroendocrine Cancer | Phase 2 | 2025-05-06 |
| Recruiting | CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension | Phase 1 / Phase 2 | 2025-04-18 |
| Recruiting | CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL) | Phase 1 / Phase 2 | 2025-04-01 |
| Recruiting | One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory | N/A | 2025-03-27 |
| Recruiting | CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | 2025-02-20 |
| Recruiting | Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia Leukemia | EARLY_Phase 1 | 2025-01-18 |
| Not Yet Recruiting | A Randomized Controlled, Open, Single-center Clinical Study Evaluating the Efficacy and Safety of Umbilical Co Refractory Immune Effector Cell-related Hemocytopenia | N/A | 2024-12-01 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases Autoimmune Diseases | Phase 1 / Phase 2 | 2024-11-23 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 / Phase 2 | 2024-10-17 |
| Recruiting | CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2024-06-18 |
| Not Yet Recruiting | Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer Advanced Breast Cancer | Phase 2 | 2024-06-01 |
| Recruiting | CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia | N/A | 2024-05-27 |
| Recruiting | Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL P B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia | N/A | 2024-04-12 |
| Recruiting | Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia Refractory/Relapsed Acute Myeloid Leukaemia | Phase 1 | 2024-04-02 |
| Recruiting | Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2024-03-22 |